Cantor Fitzgerald Reiterates Overweight on Amgen, Maintains $405 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Amgen (NASDAQ:AMGN) and maintained a price target of $405.
October 22, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Olivia Brayer has reiterated an Overweight rating on Amgen, maintaining a price target of $405. This suggests confidence in Amgen's stock performance.
The reiteration of an Overweight rating and a high price target of $405 by a reputable analyst suggests a positive outlook for Amgen's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100